Molecular Partners AGNASDAQ:MOLN
- LAST PRICE6.5800
- TODAY'S CHANGE (%)-0.1536 (-2.2811%)
- Bid / Lots6.3300/ 1
- Ask / Lots6.6600/ 2
- Open / Previous Close6.5000 / 6.7336
- Day Range
- 52 Week Range
- Volume4,193
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MOLN |
|---|---|---|
| 09:42 ET | 200 | 6.5 |
| 10:02 ET | 100 | 6.57 |
| 10:09 ET | 300 | 6.57 |
| 10:38 ET | 1300 | 6.57 |
| 11:48 ET | 500 | 6.58 |
| 11:57 ET | 100 | 6.67 |
| 12:17 ET | 100 | 6.6599 |
| 12:24 ET | 400 | 6.644 |
| 03:08 ET | 200 | 6.62 |
| 03:55 ET | 500 | 6.58 |
Jan 16, 2023
Molecular Partners Initiates Clinical Study of Trispecific Candidate MP0533 for the Treatment of Acute Myeloid Leukemia, from 1:00AM ET on Monday Jan 16, 2023 by GlobeNewswire
1:00AM ET on Monday Jan 16, 2023 by GlobeNewswire
Jan 8, 2023
Molecular Partners Provides Updates at 41st Annual JPM Healthcare Conference, from 3:00PM ET on Sunday Jan 08, 2023 by GlobeNewswire
3:00PM ET on Sunday Jan 08, 2023 by GlobeNewswire
Dec 30, 2022
Molecular Partners to Present at 41st Annual JP Morgan Healthcare Conference and Swiss Investor Conferences, from 1:00AM ET on Friday Dec 30, 2022 by GlobeNewswire
1:00AM ET on Friday Dec 30, 2022 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Molecular Partners AG | 237.2M | 1.7x | --- |
Zomedica Corp | 252.6M | -14.4x | --- |
Lineage Cell Therapeutics Inc | 238.0M | -4.8x | --- |
Rallybio Corp | 261.1M | -3.4x | --- |
Fennec Pharmaceuticals Inc | 248.6M | -11.6x | --- |
Greenwich Lifesciences Inc | 248.5M | -34.1x | --- |
Company Information
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Contact Information
- Headquarters
- Wagistrasse 14SCHLIEREN, Switzerland 8952
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- William Burns
- Chief Executive Officer, Executive Director, Member of the Management Board
- Patrick Amstutz
- Chief Financial Officer, Member of the Management Board
- Andreas Emmenegger
- Chief Operating Officer, Member of the Management Board
- Michael Stumpp
- Chief Medical Officer, Member of the Management Board
- Nicolas Leupin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $237.2M |
|---|---|
Revenue (TTM) | $205.0M |
Shares Outstanding | 36.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $3.82 |
Book Value | $3.61 |
P/E Ratio | 1.7x |
Price/Sales (TTM) | 1.2 |
Price/Cash Flow (TTM) | 1.8x |
Operating Margin | 61.35% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
